Dantrolene

CHEMBL1201288 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
314.2 g/mol
LogP
1.7
Phase
4

A muscle relaxant that acts directly on skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum, used to treat malignant hyperthermia, neuroleptic malignant syndrome, and chronic spasticity. It is the only drug effective for the life-threatening muscle rigidity of malignant hyperthermia.

Berat Molekul

314,2500 g/mol

LogP

1,70

TPSA

121,00 Ų

Lipinski RO5

Lulus

Area Terapeutik

Mekanisme Kerja

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1

InChI

InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+

Molecular Formula

C14H10N4O5

HBD / HBA

1 / 6

Ikatan yang Dapat Dirotasi

3

Atom Berat

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A muscle relaxant that acts directly on skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum, used to treat malignant hyperthermia, neuroleptic malignant syndrome, and chronic spasticity. It is the only drug effective for the life-threatening muscle rigidity of malignant hyperthermia.

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Yes, Dantrolene is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201288. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6914273. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.